Inflammation After Colon Cancer Surgery Tied to Worse Outcomes
Elevated levels of inflammatory biomarkers are associated with worse outcomes for patients with stage III colon cancer, a study suggests.
Gastrointestinal Cancers News
GASTROINTESTINAL CANCER ADVISOR
Gastrointestinal Cancers News
Larotrectinib Bests Standard Care for TRK-Fusion Positive Cancers
Larotrectinib prolongs survival when compared with non-TRK inhibitor standard care in adults with TRK fusion-positive cancers, a study suggests.
Neoadjuvant Chemotherapy Improves Colon Cancer Outcomes
Six weeks of neoadjuvant chemotherapy was associated with a higher rate of complete resection and a lower rate of disease recurrence.
Esophageal, Gastric Cancer Risks Reduced With Bariatric Surgery for Obesity
The use of bariatric surgery in patients with severe obesity is associated with a reduced incidence of esophageal and gastric cancers.
“One-Stop Shop” Screening Centers May Improve Cancer Detection
Centers that perform comprehensive cancer screening in a single appointment may enable earlier cancer diagnosis.
Declining Physical Function Is Accelerated Among Postmenopausal Cancer Survivors
Postmenopausal cancer survivors have greater declines in physical function than cancer-free control individuals, a new study suggests.
Risk of Suicide Highest in the First 6 Months After a Cancer Diagnosis
Cancer patients have an increased risk of suicide when compared with the general population in the United States, a study suggests.
System May Enable Precision Medicine in Cancer Care
A decision support system called GI TARGET may help integrate precision medicine into routine care for patients with gastrointestinal cancer, according to researchers.
Childhood, Adolescent Cancers Linked to Higher Risk of Major Psychiatric Disorders
Compared with the general population, survivors of childhood and adolescent cancers have an increased risk of 6 major psychiatric disorders.
Nonsurgical Approach Deemed Feasible for Patients With Early Rectal Cancer
A nonsurgical treatment strategy employing chemoradiotherapy is feasible for patients with early rectal cancer, a phase 3 trial suggests.
Follow-Up Colonoscopy Rates Low After Positive Stool-Based Test for Colorectal Cancer
Follow-up colonoscopy rates were 43.3% within 90 days of a positive stool-based screening test and 56.1% within 360 days.
Adding Nab-Paclitaxel to Standard Care Does Not Improve Outcomes in Biliary Tract Cancers
Adding nab-paclitaxel to gemcitabine and cisplatin does not improve outcomes in newly diagnosed, advanced biliary tract cancers, a phase 3 trial suggests.
Risk of Advanced Neoplasm Low 10+ Years After Negative Colonoscopy
The prevalence of advanced colorectal neoplasms was 40% to 50% lower among patients who underwent repeated screening at least 10 years after a negative colonoscopy.
Trifluridine Plus Tipiracil and Bevacizumab Deemed New Standard Care for Refractory Metastatic Colorectal Cancer
Adding bevacizumab to treatment with trifluridine and tipiracil improved outcomes in patients with refractory metastatic colorectal cancer in the phase 3 SUNLIGHT trial.
Benefit Seen With SBRT Before Sorafenib in Advanced HCC
SBRT prior to sorafenib improved outcomes, compared with sorafenib alone, in a phase 3 trial of patients with advanced hepatocellular carcinoma.
Tukysa Combo Approved for RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
The approval was based on data from the phase 2 MOUNTAINEER trial, which included patients with HER2-positive. unresectable or metastatic colorectal cancer.
ctDNA Monitoring Shows Promise for Anal Cancer Patients Receiving Chemoradiation
Monitoring of ctDNA may be useful for early response assessment in patients with anal cancer receiving chemoradiation, a study suggests.
Botensilimab Plus Balstilimab Yields Durable Responses in Refractory Metastatic Colorectal Cancer
Combination botensilimab and balstilimab elicits durable responses in refractory, metastatic, microsatellite-stable colorectal cancer, a phase 1 trial suggests.
NAPOLI-3 Results Support NALIRIFOX for Metastatic Pancreatic Cancer
NALIRIFOX outperformed treatment with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer in the NAPOLI-3 trial.
Nanvuranlat Improves PFS in Heavily Pretreated, Advanced Biliary Tract Cancer
Nanvuranlat improved progression-free survival, compared with placebo, in heavily pretreated patients with advanced biliary tract cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Expertscape
Loading... 
Loading...